Your session is about to expire
← Back to Search
AAV5-hFIXco-Padua (AMT-061) for Hemophilia B
Study Summary
This trial is a study to test a new gene therapy for hemophilia B.
- Hemophilia B
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2023 Phase 2 trial • 3 Patients • NCT03489291Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have been treated with FIX protein for more than 20 days in the past.Only males can participate.You have been exposed to Hepatitis B or C in the past, but you are currently taking medicine to control it.
- Group 1: Single infusion of AMT-061
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Could you provide information regarding the scope of this research in North America?
"Currently, this research is operating out of 4 locations spread across the United States. Sites can be found in Sacramento, San Diego and Ann Arbor as well as another undisclosed site. It would be prudent to select a clinic that is closest to your home address so you can minimize travel needs if accepted into the study."
Is AAV5-hFIXco-Padua (AMT-061) a safe treatment option for individuals?
"While Phase 2 trials provide some evidence of safety, they lack efficacy data. Thus, our internal team at Power assigned AAV5-hFIXco-Padua (AMT-061) a score of two on the safety scale from 1 to 3."
Is this study currently seeking volunteers?
"Clinicaltrials.gov provides evidence that this study, which was first published on July 24th 2018 and last updated on May 17th 2022, is not currently recruiting patients. Nonetheless, 89 other trials are actively enlisting participants at the moment."
Share this study with friends
Copy Link
Messenger